- Home
- FLC vs MDWD Comparison
FLC vs MDWD Comparison
Compare FLC & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLC
- MDWD
- Stock Information
- Founded
- FLC 2003
- MDWD 2000
- Country
- FLC United States
- MDWD Israel
- Employees
- FLC N/A
- MDWD N/A
- Industry
- FLC Trusts Except Educational Religious and Charitable
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- FLC Finance
- MDWD Health Care
- Exchange
- FLC Nasdaq
- MDWD Nasdaq
- Market Cap
- FLC 180.6M
- MDWD 184.8M
- IPO Year
- FLC N/A
- MDWD 2014
- Fundamental
- Price
- FLC $16.59
- MDWD $19.02
- Analyst Decision
- FLC
- MDWD Strong Buy
- Analyst Count
- FLC 0
- MDWD 1
- Target Price
- FLC N/A
- MDWD $25.00
- AVG Volume (30 Days)
- FLC 37.8K
- MDWD 61.7K
- Earning Date
- FLC 01-01-0001
- MDWD 11-26-2024
- Dividend Yield
- FLC 6.64%
- MDWD N/A
- EPS Growth
- FLC N/A
- MDWD N/A
- EPS
- FLC N/A
- MDWD N/A
- Revenue
- FLC N/A
- MDWD $19,720,000.00
- Revenue This Year
- FLC N/A
- MDWD $10.37
- Revenue Next Year
- FLC N/A
- MDWD $26.36
- P/E Ratio
- FLC N/A
- MDWD N/A
- Revenue Growth
- FLC N/A
- MDWD N/A
- 52 Week Low
- FLC $12.62
- MDWD $11.04
- 52 Week High
- FLC $15.45
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- FLC 44.20
- MDWD 61.79
- Support Level
- FLC $16.46
- MDWD $15.80
- Resistance Level
- FLC $16.89
- MDWD $18.25
- Average True Range (ATR)
- FLC 0.22
- MDWD 0.88
- MACD
- FLC -0.01
- MDWD 0.07
- Stochastic Oscillator
- FLC 36.00
- MDWD 95.27
About FLC Flaherty & Crumrine Total Return Fund Inc
Flaherty & Crumrine Total Return Fund Inc is a diversified, closed-end investment management company. Its investment objective is to provide its common shareholders with a high current income. The fund's secondary investment objective is capital appreciation.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.